此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Colorectal Cancer Detected by 1H-NMR Spectroscopy (BIOCOR)

2018年8月19日 更新者:Prof. dr. Michiel Thomeer、Hasselt University

Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy: a New Tool to Detect Colorectal Cancer?

The hypothesis of the present study is that metabolic phenotyping of blood plasma allows to (i) discriminate between colorectal cancer patients and control subjects and (ii) identify new biomarkers for colorectal cancer. In order to test this hypothesis, the investigators will apply proton nuclear magnetic resonance (1H-NMR) spectroscopy to perform metabolic phenotyping of blood plasma in 50 colorectal cancer patients and 50 control subjects. Multivariate statistics will be performed to assess the discriminative power of the applied methodology in distinguishing between both groups and to identify metabolites with potential as biomarkers for colorectal cancer.

研究概览

详细说明

Colorectal cancer is one of the most common and deadliest cancers worldwide. Since tumor stage at time of diagnosis is a critical determinant of patient outcome, early detection of colorectal cancer by screening modalities holds the key to improving patient survival. However, current tests, i.e. fecal occult blood testing and colonoscopy, are inadequate for first line screening of colorectal cancer due to limited accuracy and low participation rates, respectively. Therefore, there is an urgent need for new and accurate tests that can be used for en masse screening of colorectal cancer. A blood-based test represents a promising alternative as it takes little time, poses minimal risk to the patient, and is therefore very likely to lead to high participation rates. The development of an effective blood-based screening tool is based on the identification of biomarkers in the blood that are sensitive and specific for colorectal cancer. Studying the metabolic phenotype of colorectal cancer may help to identify such biomarkers since the metabolism of cancer cells is known to differ significantly from that of normal cells. More specifically, the entire metabolism of cancer cells is reprogrammed to increase anabolic reactions that favor cell growth and cell survival.

The hypothesis of the present study is that metabolic phenotyping of blood plasma allows to (i) discriminate between colorectal cancer patients and control subjects and (ii) identify new biomarkers for colorectal cancer. In order to test this hypothesis, The investigators will apply proton nuclear magnetic resonance (1H-NMR) spectroscopy to perform metabolic phenotyping of blood plasma in 50 colorectal cancer patients and 50 control subjects. Multivariate statistics will be performed to assess the discriminative power of the applied methodology in distinguishing between both groups and to identify metabolites with potential as biomarkers for colorectal cancer.

研究类型

观察性的

注册 (实际的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Genk、比利时、3600
        • Ziekenhuis Oost-Limburg

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 90年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

概率样本

研究人群

Colorectal cancer patients and control subjects who undergo a coloscopy without diabetes and/or a history of cancer during the past 5 years, of an age between 40 and 90 years and willing to provide written informed consent.

描述

Inclusion Criteria:

  • The subject has undergone a colonoscopy or is scheduled to undergo a colonoscopy in the future
  • The subject is aged between 40 and 90 years
  • The subject understands the study-specific procedures and provides written informed consent before any study-specific procedures are performed

Exclusion Criteria:

  • No fasting starting from 10 p.m. the day prior to blood sampling
  • Medication intake on the morning of blood sampling
  • Diabetes
  • History of cancer during the past 5 years
  • Treatment for cancer during the past 5 years
  • Inflammatory bowel disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Control group-Blood sampling
-subjects with a normal colonoscopy
Determine the metabolic phenotype of blood plasma by NMR spectroscopy
其他名称:
  • Metabolic phenotype
determine amount and type of free circulating miRNA in blood plasma
其他名称:
  • free circulating miRNA
Study group-Blood sampling
- subjects with colorectal cancer after colonoscopy
Determine the metabolic phenotype of blood plasma by NMR spectroscopy
其他名称:
  • Metabolic phenotype
determine amount and type of free circulating miRNA in blood plasma
其他名称:
  • free circulating miRNA

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
metabolic phenotype of colorectal cancer
大体时间:day 1
Significant metabolic changes in blood plasma of colorectal cancer patients compared with control subjects
day 1

次要结果测量

结果测量
措施说明
大体时间
tumor histology
大体时间:day 1
subtype of histology of the colorectal tumor (according to WHO histological classification of tumors of the colon and rectum)
day 1
tumor stage
大体时间:Day 1
stage of the colorectal tumor, defined by the TNM classification system (7th edition)
Day 1

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:peter Adriaensens, prof. dr.、Hasselt University
  • 首席研究员:Michiel thomeer, prof. dr.、Ziekenhuis Oost-Limburg, Hasselt University
  • 学习椅:Liesbet Mesotten, prof. dr.、Ziekenhuis Oost-Limburg, Hasselt University
  • 学习椅:Philip Caenepeel, prof. dr.、Ziekenhuis Oost-Limburg, Hasselt University
  • 学习椅:Kirsten Stinkens, dr.、Hasselt University
  • 学习椅:Evelyne Louis, PhD student、Hasselt University
  • 学习椅:Robby Louis, student、Hasselt University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年12月1日

初级完成 (实际的)

2015年6月1日

研究完成 (实际的)

2015年9月1日

研究注册日期

首次提交

2015年2月10日

首先提交符合 QC 标准的

2015年2月10日

首次发布 (估计)

2015年2月16日

研究记录更新

最后更新发布 (实际的)

2018年8月21日

上次提交的符合 QC 标准的更新

2018年8月19日

最后验证

2018年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅